新锐医药国际控股有限公司(06108)董事会宣布，已向股东提呈普通决议案，以授予董事一般及无条件授权，在股东周年大会通过后，可于香港联交所或其他获准交易所购回公司不超过当日已发行股份总数(不包括库存股份)的10%。
公司现有已发行股份数约为200,616,665股，计划购回股份所需资金将根据百慕达法及相关上市规则，从本公司合法可动用的资金中拨付。董事会指出，回购股份有助于提升公司每股收益、优化资本结构，并相信此举符合公司及股东的最佳利益。
根据公告，相关授权有待2026年6月18日召开的股东周年大会审议批准。本公司提醒股东需留意投票及股份过户登记的具体安排。董事会建议股东审慎行使表决权。根据公告，若该授权顺利获得通过，董事会将在适当情况下行使回购权，以实现为股东创造更大回报的目标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.